Skip to main content
. 2022 Aug 18;27(12):1041–1047. doi: 10.1093/oncolo/oyac158

Table 2.

Objective response to cabozantinib in the whole population (n = 52)

Outcomes Objective response rate, n (%)
Best overall response 9 (17.3%)
Complete response 2 (3.8%)
Partial response 7 (13.5%)
Stable disease 26 (50%)
 >6 months 15 (29%)
 <6 months 11 (21%)
Progressive disease 17 (32.7%)
Clinical benefit 24 (46%)